Phase I Clinical Study to Evaluate the Safety, Tolerability, and Initial Efficacy of SSGJ-706 Monotherapy for Patients With Advanced Solid Tumors
Latest Information Update: 07 Aug 2024
At a glance
- Drugs 706 3SBio (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Sunshine Guojian Pharmaceutical
Most Recent Events
- 07 Aug 2024 New trial record